Peptides A-Z · Research Guide
This review explains what a gh peptide is, how the main classes differ in mechanism and why potency depends on the research endpoint. It aims to help researchers and advanced users…
The content focuses on evidence from head-to-head human trials and modern reviews, clarifying when an agent is described as more potent for acute GH peaks versus when long acting analogs are used to raise IGF-1 over time. It does not provide medical advice and encourages consultation of primary references for study planning.
A gh peptide is a compound that stimulates the growth hormone axis, typically by acting either at the ghrelin receptor or at the pituitary growth hormone releasing hormone receptor. The two main classes are GHRP-class secretagogues, which act through the ghrelin receptor, and GHRH analogs, which act at the pituitary, and both are described in modern pharmacology syntheses and endocrine guidance Frontiers in Endocrinology review
Understanding which agent is the “most powerful” requires defining the outcome: some studies measure acute peak GH release after a single dose, while others evaluate mean GH or IGF-1 over days to weeks. That distinction matters because different mechanisms produce different profiles and research goals must match the chosen outcome Endocrine Society clinical practice guideline
Evidence on comparative potency combines older controlled human trials and later pharmacology reviews. Direct, standardised head-to-head trials across all commonly discussed agents are limited, so comparative statements draw on a mix of trial data and synthesis papers rather than large contemporary randomised series Frontiers in Endocrinology review
At a basic level, gh peptide actions split into two mechanisms. GHRP-class compounds such as GHRP-2, GHRP-6 and ipamorelin are ghrelin receptor agonists that trigger a rapid release of GH from the pituitary via the GHSR receptor, producing sharp early peaks after dosing Frontiers in Endocrinology review. See a head-to-head comparison for practical summaries comparison hub
GHRH analogs act directly on the pituitary GHRH receptor and tend to raise mean GH and downstream IGF-1 over a longer timeframe when dosed repeatedly; long acting analogs can produce sustained elevations in mean GH and IGF-1 rather than single high peaks Journal of Clinical Endocrinology & Metabolism on CJC-1295
To make the difference concrete, consider a simple three step analogy. Step one, receptor engagement: GHRP-class compounds engage the ghrelin receptor in a way that mimics a rapid stimulus. Step two, pituitary response: that stimulus drives a sharp GH pulse. Step three, downstream cascade: repeated pulses or long acting GHRH analog dosing produce accumulated increases in IGF-1 over time, which is a different endpoint than a single peak Frontiers in Endocrinology review
Pharmacologic selectivity matters because some secretagogues also influence other pituitary axes. Certain GHRP-class agents can stimulate ACTH and cortisol or raise prolactin, which changes the monitoring profile for a study and may influence agent selection Endocrine Society clinical practice guideline
GHRP-class compounds bind the growth hormone secretagogue receptor, abbreviated GHSR, producing a rapid GH surge after dosing. This pathway explains why many studies using single doses of GHRP-class agents focus on peak GH as the primary endpoint Frontiers in Endocrinology review
GHRH analogs act at the pituitary to increase pulsatile release and, with longer acting molecules or repeated dosing, raise mean GH and IGF-1. This pattern is more relevant when the research question targets systemic IGF-1 rather than immediate GH peaks Journal of Clinical Endocrinology & Metabolism on CJC-1295
Some GHRP-class peptides can provoke non-GH pituitary responses, including increases in ACTH, cortisol and prolactin; those off target hormonal changes are important for study safety monitoring and interpretation of endocrine readouts Endocrine Society clinical practice guideline
Below we summarise representative agents and the profiles typically reported in the literature. This section focuses on pharmacologic characteristics rather than recommendations for use in clinical practice or therapy. See our education article on growth hormone peptides for background growth hormone peptides explained
GHRP-2 and GHRP-6 are classic ghrelin receptor agonists studied head-to-head in controlled human trials, where GHRP-2 typically produced larger acute GH peaks than GHRP-6 in those comparisons head-to-head GHRP-2 versus GHRP-6 trial
Ipamorelin is commonly described as producing GH release with less ACTH, cortisol and prolactin stimulation compared with some other secretagogues, a finding reported in clinical trials and reviews and relevant when selectivity is a priority Ipamorelin clinical trial. For general peptide context see a peptide guide peptides for muscle growth
CJC-1295 with a drug affinity complex is a long acting GHRH analog that has been shown in trial data to increase mean GH and IGF-1 over days to weeks, so it is often discussed when the research goal is a persistent IGF-1 elevation rather than a single peak CJC-1295 study. See a practical guide that covers these agents growth hormone peptides guide
Sermorelin is an older, shorter acting GHRH analog with lower acute potency compared with many secretagogues and is mainly referenced in the literature for diagnostic or historical purposes rather than as a leading high potency agent Sermorelin review
GHRP-2, high acute peak GH; GHRP-6, lower acute peak than GHRP-2; ipamorelin, GH release with greater selectivity; CJC-1295, sustained mean GH and IGF-1; sermorelin, shorter acting and lower acute potency Frontiers in Endocrinology review
Controlled human studies from the 1990s and later pharmacology reviews are the main sources for comparative potency statements, with GHRP-2 and ipamorelin featuring in head-to-head or focused trials and CJC-1295 represented in longer acting clinical studies head-to-head GHRP-2 versus GHRP-6 trial
Researchers typically discuss GHRP-2 where acute GH peaks are the endpoint, ipamorelin where selectivity is important for adrenal or prolactin axes, and CJC-1295 when sustained IGF-1 elevation is the target; sermorelin appears mainly in diagnostic or historical contexts Ipamorelin clinical trial
Direct comparisons of acute GH peaks come primarily from older controlled trials. Multiple human studies from the 1990s and 2000s reported that GHRP-2 often elicits higher acute GH peaks than GHRP-6 in head-to-head comparisons, a repeated finding across those trial series head-to-head GHRP-2 versus GHRP-6 trial
Ipamorelin has been evaluated in trials showing GH release with minimal concurrent ACTH, cortisol and prolactin stimulation, which gives it a more selective endocrine profile compared with some other secretagogues Ipamorelin clinical trial
Limitations in these comparisons include small sample sizes, varied dosing regimens and different endpoints across studies, which make direct ranking across all agents challenging and underline the need for standardised, contemporary head-to-head trials Frontiers in Endocrinology review
Older controlled trials report peak GH responses as short term pharmacodynamic endpoints and consistently show that GHRP-2 produces larger acute GH peaks than GHRP-6 in direct comparisons; this is the basis for classifying GHRP-2 as more potent for single dose peak responses head-to-head GHRP-2 versus GHRP-6 trial
Trial evidence that ipamorelin triggers GH release without notable ACTH, cortisol or prolactin increases supports its characterization as relatively selective, a property that may be relevant for study designs concerned about those accompanying endocrine changes Ipamorelin clinical trial
Across the literature, differences in dosing, timing of sampling and small cohorts reduce confidence in definitive rankings, and more modern, standardised head-to-head trials would clarify comparative potency across the commonly discussed agents Frontiers in Endocrinology review
Safety profiles vary by class. GHRP-class peptides can increase ACTH, cortisol and prolactin, which are clinically meaningful differences that should inform monitoring plans in research settings Endocrine Society clinical practice guideline
Ipamorelin’s comparatively favorable selectivity, with less stimulation of adrenal and prolactin pathways in trials, is often cited where reducing off target hormonal stimulation is a priority Ipamorelin clinical trial
Supply and product quality variability are important practical considerations for research. Differences in synthesis, storage and regulatory oversight across suppliers mean that investigators should document sourcing and batch information and consider independent verification where possible Frontiers in Endocrinology review. See guidance on how to find a legitimate peptide provider how to find a legitimate peptide provider
Recommended monitoring parameters in most research contexts include baseline and follow up measurements of GH and IGF-1, morning cortisol and prolactin where a GHRP-class agent is used, and documentation of assay methods to allow cross study comparison Endocrine Society clinical practice guideline
Investigators should record dosing regimens and sampling schedules carefully as those variables influence both acute peak and mean GH outcomes; reporting these details improves interpretability and comparability across studies Frontiers in Endocrinology review
A common mistake is to conflate acute GH peak potency with sustained increases in IGF-1; these are different endpoints measured in different study designs and they reflect distinct pharmacologic actions Frontiers in Endocrinology review
Relying on a single small trial to declare one agent categorically superior ignores variability in dosing, timing and assay methods. Many comparative claims derive from older, limited trials or from synthesis papers summarising heterogeneous data head-to-head GHRP-2 versus GHRP-6 trial
Another pitfall is to assume supplier labels guarantee consistency; regulatory and quality variability in research peptide supplies means investigators should verify identity and stability when possible and document supply chain details in study records Frontiers in Endocrinology review
Scenario A: Research focused on acute GH peak responses. If the study endpoint is a rapid, single dose GH peak, the human head-to-head literature commonly references GHRP-2 as producing larger acute peaks than GHRP-6, and this historical finding often guides agent selection for peak response studies head-to-head GHRP-2 versus GHRP-6 trial
Decision pointer A: Prioritise short sampling windows for peak detection and predefine the peak window in the protocol to ensure consistent comparisons across subjects and agents Frontiers in Endocrinology review
Scenario B: Studies aiming for sustained IGF-1 elevation. For research endpoints that require a persistent increase in IGF-1, long acting GHRH analogs such as CJC-1295 with a drug affinity complex have been shown in clinical trial data to raise mean GH and IGF-1 over days to weeks and are commonly discussed for this objective CJC-1295 study
Which agent is most powerful depends on the defined endpoint: GHRP-2 is commonly reported to elicit the largest acute GH peaks, while long acting GHRH analogs such as CJC-1295 produce sustained increases in mean GH and IGF-1; ipamorelin is noted for greater selectivity with less ACTH, cortisol and prolactin stimulation.
Scenario C: Prioritising selectivity to minimise adrenal or prolactin effects. When the study objective emphasises minimising ACTH, cortisol or prolactin changes, ipamorelin is often referenced as producing GH release with minimal stimulation of those axes in human trials, which can reduce confounding hormonal responses in the study outcome Ipamorelin clinical trial
Decision pointer C: Include baseline adrenal and prolactin measures and plan follow up sampling after dosing to detect any off target axis activation, documenting assay methods and timing to aid interpretation Endocrine Society clinical practice guideline
Quick decision checklist: 1) define your target outcome, peak GH or sustained IGF-1, 2) prioritise human head-to-head data where available, 3) check selectivity and monitoring needs, 4) verify supply quality and batch documentation Frontiers in Endocrinology review. For information on medical grade versus research grade peptides see medical grade vs research grade peptides
How to read claims: ask whether the evidence cited is a controlled human trial or a pharmacology review, whether the endpoint is an acute peak or a sustained IGF-1 change, and whether off target hormone effects were measured and reported Endocrine Society clinical practice guideline
Next steps and primary references: for acute peak comparisons see the head-to-head GHRP-2 versus GHRP-6 trial; for long acting GHRH analog data see the CJC-1295 clinical study; for monitoring and guidance consult endocrine society documents and pharmacology reviews head-to-head GHRP-2 versus GHRP-6 trial
Power depends on the measured endpoint, for example acute GH peak after a single dose versus sustained GH or IGF-1 over time, and on trial design and dosing.
In older head-to-head trials GHRP-2 produced larger acute GH peaks than GHRP-6, but potency depends on the endpoint and other agents like long acting GHRH analogs are more relevant for sustained IGF-1.
Plan baseline and follow up GH and IGF-1, measure morning cortisol and prolactin as appropriate, record dosing and supply details, and use consistent assays.
Bottom line
In practice, choosing a gh peptide for research requires matching the agent to the study endpoint, planning appropriate monitoring and documenting supply details. Use the cited primary sources and endocrinology guidance when designing protocols.
If you need a concise comparison for protocol review, use the checklist in this article as a starting point and consult the primary trial and review literature referenced above.
The 2-minute quiz sorts the research by what you actually want to achieve, then points you to the guides that apply to you.